Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor
Human Cell · 2024
DOI: 10.1007/s13577-024-01066-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Xiaoyan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, Receptors, Chimeric Antigen, ErbB Receptors, Disease Models, Animal. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Suqian Sci & Tech Program.
Abstract (Originalsprache)
Chimeric antigen receptor T (CART) cell therapy has demonstrated promising potential in the treatment of hematologic malignancies. However, its application to solid tumors is limited due to the restrictive nature of the tumor microenvironment, resulting in functional failure and poor persistence of CART cells. Overexpression of Bcl-2 in human CART cells (hCART) has been found to significantly enhance their anti-apoptotic effects both in vitro and in vivo. Nevertheless, the evaluation of hCART cells in preclinical studies has predominantly relied on immunodeficient mice xenograft tumor models, making it challenging to assess the impact of hCART cells on normal tissues and the immune system. We established a murine CART (mCART) that overexpresses Bcl-2 and targets the epidermal growth factor receptor variant III (EGFRvIII), named EGFRvIII·mCART-Bcl2. It demonstrated superior proliferation, cytotoxicity, and anti-apoptotic capabilities in vitro. In an immunocompetent mouse model of abdominal metastasis of colorectal cancer, EGFRvIII·mCART-Bcl2 exhibited improved survival of CART in the abdomen, increased tumor clearance, and significantly prolonged overall mouse survival. In summary, our study provides evidence that the introduction of Bcl-2 into mCART cells can enhance their therapeutic efficacy against solid tumors while ensuring safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.
- Department of General Surgery, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.
- School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China. 1974253281@qq.com.
- School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China.
- School of Life Sciences, Jiangsu University, Zhenjiang, 212013, China. yufeng@ujs.edu.cn.
Förderung
- Suqian Sci & Tech Program
Zitieren
APA
Wang, X., Liu, G., Shi, X., Wang, Y., Jiang, B., Liu, W., Dai, A., Zhang, X., & Yu, F. (2024). Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor. Human Cell. https://doi.org/10.1007/s13577-024-01066-x
Vancouver
Wang X, Liu G, Shi X, Wang Y, Jiang B, Liu W, et al. Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor. Human Cell. 2024. doi:10.1007/s13577-024-01066-x
BibTeX
@article{Wang2024,
author = {Wang, Xiaoyan and Liu, Guodong and Shi, Xianggang and Wang, Yuxing and Jiang, Bo and Liu, Wei and Dai, Anran and Zhang, Xiangzhi and Yu, Feng},
title = {Overexpressing Bcl-2 enhances murine chimeric antigen receptor T cell therapy against solid tumor},
journal = {Human Cell},
year = {2024},
doi = {10.1007/s13577-024-01066-x}
}
EUVIMED